5‐alpha‐reductase inhibitors and the risk of diabetes mellitus: A nationwide population‐based study

Abstract

Therapy with 5ARI may decrease the five-year risk of type 2 DM in the BPH patients younger than 65 years. Further mechanistic research is warranted to validate the results.